Biofil Chemicals and Pharmaceuticals Limited (BOM:524396)
30.40
+0.15 (0.50%)
At close: Nov 6, 2026
BOM:524396 Revenue
Biofil Chemicals and Pharmaceuticals had revenue of 124.13M INR in the quarter ending June 30, 2026, with 33.98% growth. This brings the company's total for the last twelve months to 346.26M, up 1.26% year-over-year. In the fiscal year ending March 31, 2026, Biofil Chemicals and Pharmaceuticals had annual revenue of 283.95M, down -15.45%. That makes Biofil Chemicals and Pharmaceuticals the 40,900th largest company in the world by revenue and 4,017th in India.
Revenue (ttm)
346.26M
Revenue Growth
+1.26%
P/S Ratio
1.43
Revenue / Employee
14.43M
Employees
24
Market Cap
494.72M
Revenue by Segment
- Pharma Division 189.63M 66.8%
- Chemical Division 94.32M 33.2%
Fiscal year ended Mar 31, 2026 See the full BOM:524396 breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 283.95M | -51.87M | -15.45% |
| Mar 31, 2025 | 335.82M | -68.27M | -16.89% |
| Mar 31, 2024 | 404.09M | 103.74M | 34.54% |
| Mar 31, 2023 | 300.35M | 76.53M | 34.19% |
| Mar 31, 2022 | 223.82M | -134.27M | -37.50% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Murae Organisor | 8.59B |
| Mangalam Drugs & Organics | 2.32B |
| JFL Life Sciences | 2.00B |
| Rajnish Wellness | 1.68B |
| ANG Lifesciences India | 835.87M |
| Sandu Pharmaceuticals | 696.24M |
| Onyx Biotec | 694.69M |
| Phaarmasia | 486.17M |